C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 877 TWD 1.5%
Market Cap: 135.6B TWD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+21%
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

Price Targets Summary
Caliway Biopharmaceuticals Co Ltd

Wall Street analysts forecast Caliway Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Caliway Biopharmaceuticals Co Ltd is 1 060.8 TWD with a low forecast of 1 050.4 TWD and a high forecast of 1 092 TWD.

Lowest Forecast
Wall Street Target
1 050.4 TWD
20% Upside
Average Forecast
Wall Street Target
1 060.8 TWD
21% Upside
Highest Forecast
Wall Street Target
1 092 TWD
25% Upside
Lowest
Price Target
1 050.4 TWD
20% Upside
Average
Price Target
1 060.8 TWD
21% Upside
Highest
Price Target
1 092 TWD
25% Upside
Caliway Biopharmaceuticals Co Ltd Competitors:
Price Targets
SHILPAMED
Shilpa Medicare Ltd
36% Upside
4577
Daito Pharmaceutical Co Ltd
103% Upside
LABB
Genomma Lab Internacional SAB de CV
35% Upside
C
000661
Changchun High & New Technology Industries Group Inc
4% Upside
SHILPAMED
Shilpa Medicare Ltd
36% Upside
4577
Daito Pharmaceutical Co Ltd
103% Upside
LABB
Genomma Lab Internacional SAB de CV
35% Upside
C
000661
Changchun High & New Technology Industries Group Inc
4% Upside
ORMP
Oramed Pharmaceuticals Inc
42% Upside
S
SBBC
Simply Better Brands Corp
101% Upside
T
1666
Tong Ren Tang Technologies Co Ltd
26% Upside
688185
CanSino Biologics Inc
31% Upside

Revenue
Forecast

Revenue Estimate
Caliway Biopharmaceuticals Co Ltd

For the last 4 years the compound annual growth rate for Caliway Biopharmaceuticals Co Ltd's revenue is 44%. The projected CAGR for the next 2 years is 1 065%.

44%
Past Growth
1 065%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Caliway Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Caliway Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Caliway Biopharmaceuticals Co Ltd's stock price target?
Price Target
1 060.8 TWD

According to Wall Street analysts, the average 1-year price target for Caliway Biopharmaceuticals Co Ltd is 1 060.8 TWD with a low forecast of 1 050.4 TWD and a high forecast of 1 092 TWD.

What is Caliway Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
1 065%

For the last 4 years the compound annual growth rate for Caliway Biopharmaceuticals Co Ltd's revenue is 44%. The projected CAGR for the next 2 years is 1 065%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.